CN106336404A - Benzoquinazolinetyrosine kinaseinhibitor containing fluorobenzene and thiophene-sulfonamide structure, and application thereof - Google Patents
Benzoquinazolinetyrosine kinaseinhibitor containing fluorobenzene and thiophene-sulfonamide structure, and application thereof Download PDFInfo
- Publication number
- CN106336404A CN106336404A CN201610659638.5A CN201610659638A CN106336404A CN 106336404 A CN106336404 A CN 106336404A CN 201610659638 A CN201610659638 A CN 201610659638A CN 106336404 A CN106336404 A CN 106336404A
- Authority
- CN
- China
- Prior art keywords
- compound
- cell
- tumor
- kinase
- tyrosine kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The invention relates to the field of tumor diseases. Specifically, the invention relates to a novel benzoquinazolinetyrosine kinaseinhibitor containing a fluorobenzene and thiophene-sulfonamide structure, and a preparation method and an application thereof in preparation of drugs for treating tumor diseases.
Description
Technical field
The present invention relates to the drug world of tumor.In particular it relates to have medicative to above-mentioned disease
A kind of tyrosine kinase inhibitor containing fluorobenzene and the new Benzoquinazole analog derivative of thiophenesulfonyl amine structure, its preparation side
Method and purposes.
Background technology
Tumor is seriously to threaten one of human life and the principal disease of quality of life, and according to who statistics, the whole world is dead every year
Patient about 6,900,000 in tumor.Due to the change of living environment and life habit, in the work of poor environment and some unfavorable factors
With under, the M ＆ M of tumor is in rapid increase trend in recent years.
Protein kinase forms one of maximum family of people's fermentoid, and to be adjusted on protein by adding phosphate group
The many different signal transduction processes of section.Especially, tyrosine kinase phosphorylating protein is in the phenol moieties of tyrosine residue.Cheese
Histidine kinase family includes controlling the member of cell growth, migration and differentiation.Abnormal kinase activity has been directed to many mankind
Disease, including cancer, autoimmune disease and inflammatory diseasess.Because protein kinase belongs to the crucial regulation of cellular signal transduction
Agent, their offers adjust the target of cell function with small molecule kinase inhibitors, and therefore become good medicine and set
Meter target.Except the treatment of kinase mediated lysis, the selectivity of kinase activity and effective inhibitor can be additionally used in studying
Cell signaling processes and the other cell target with therapeutic potential of identification.
The conventional treatment to tumor by discovery tumor and destroys to realize, now with to cellular signal transduction way
What footpath was studied deepens continuously, and it is more and more deep that people understand to the oncogene of inside tumor cells and the effect of antioncogene,
Increasingly receive publicity for the new antitumor drug of the specific molecular shot design of tumor, become the hot fields of research,
And anti-tumor drugs targeting has also been applied to clinic as a kind of new Therapeutic Method, and obtain notable in recent years
Progress.It is well known that protein tyrosine kinase (protein tyrosinekinases, ptk) signal path and tumor cell
Propagation, differentiation, migration and apoptosis have substantial connection, using ptk inhibitor interference or block tyrosine kinase path can use
In oncotherapy.Ptk be normal with abnormality proliferation during becoming in the cancer protein that plays an important role and proto-protein family
Member, is a kind of a kind of enzyme of the tyrosine residue phosphorylation that can optionally make different substrates, and they are catalyzed the γ-phosphoric acid of atp
Group-transfer, on the tyrosine residue of many key proteins, makes phenolic hydroxyl group phosphorylation.Protein tyrosine kinase is divided into receptor cheese
Histidine kinase (receptor tyrosine kinase, rtk), nonreceptor tyrosine kinase and ir and janus kinases etc.
(robinson d.r., et al, oncogene, 2000,19,5548-5557), wherein most is receptor type tyrosine kinase
(rtk).Rtk is that one kind has intrinsic protein tyrosine kinases, participates in the regulation and control of various kinds of cell activity, replicates in active cell
The conduction of mitogenesis signal in there is extremely important status, regulate and control growth and the differentiation of cell.All of rtk is
Belong to i type memebrane protein, its molecule has similar topological structure: a big glycosylated extracellular ligand binding domain, dredge for one
The single pass transmembrane area of water, and an intracellular tyrosine kinase catalyst structure domain and regulating and controlling sequence.The combination of part is (as epidermis
Somatomedin (egf) and the combination of egfr) lead to the kinase activation of the internal Coded of recipient cell to activate, make in target protein
Key tyrosine phosphorylation, lead to proliferation signals cross over cytoplasma membrane transduction.
In recent years, people are devoted to suppressing cellular signal transduction pathways to develop new target spot antitumor drug.Signal turns
Lead existence and the proliferation signal that inhibitor lowers tumor, promote apoptosis, rather than pass through cytotoxicity, therefore selectivity
Higher, toxic and side effects are less.Have ten several signal transduction inhibitors at present and be applied to clinical treatment tumour, predominantly tyrosine
What the compound of kinase inhibitor series antineoplastic medicament, wherein 4- (substituted anilinic) quinazoline structure type was developed relatively becomes
Ripe, such as the micromolecular inhibitor gefitinib (iressa) of egfr tyrosine kinase target spot, erlotinib (tarceva) and
Lapatinib (lapatinib) etc..
Gefitinib (gefitinib), trade name iressa (IRESSA), the egfr tyrosine of astrazeneca exploitation
Kinase inhibitor, is the epidermal growth factor recipient tyrosine kinase inhibitor entering clinical research earliest, in 2002 in day
This listing, next year lists in the U.S., for treating the late period previously receiving chemotherapy or Metastatic Nsclc
(nsclc).Erlotinib (erlotinib), trade name tarceva (Tarceva), the egfr tyrosine kinase of osi company exploitation
Inhibitor, is transferred from genentech and Roche Holding Ag.List in the U.S., for treating nsclc and cancer of pancreas within 2004.Belong to
The first generation treat nsclc aniline quinazoline type small molecular inhibitor, be also currently the only confirmed to Advanced Non-Small Cell
Pulmonary carcinoma has the egfr tyrosine kinase inhibitor of survival advantage, all effective to all kinds of Patients with Non-small-cell Lungs, and toleration
Good, no bone marrow depression and neurotoxicity, can significantly extend life cycle, improve patients ' life quality.
Small molecule tyrosine kinase inhibitors, as new anti-tumor drugs targeting, are that the treatment and prevention of tumor open
One fan new window, and its side effect is slight, has good toleration.Although having more than 10 small molecule tyrosine kinase at present
Inhibitor has made very big contribution for clinical cancer therapy, but still needs to find some than existing tyrosine-kinase enzyme level
Agent has the other compound of the pharmacological characteristics of more preferable activity in vivo and/or improvement.Therefore develop new improved or
More efficient tyrosine kinase inhibitor, gains more insight into the relation between such medicine and known target protein and its performance
The mechanism of antitumor action has great importance to clinical therapy of tumor.
The invention discloses a kind of new Benzoquinazole class tyrosine kinase suppression containing fluorobenzene and thiophenesulfonyl amine structure
Preparation, this compound can be used for preparing tumor.
Content of the invention
It is an object of the present invention to provide a kind of tyrosine kinase inhibitor with formula i.
It is a further object to provide the method that preparation has the compound of formula i.
It is also another object of the present invention to provide the compound containing formula i is as effective ingredient, and it is in treatment tumor
The application of aspect.
In conjunction with the purpose of the present invention, present invention is specifically described.
The compound that the present invention has formula i has a following structural formula:
Formula i compound of the present invention can be synthesized by following route:
First with n-buli process, the aryl lithium intermediate obtaining and benzaldehyde iii react compound ii, obtain compound
iv；Compound iv and thiophene sulfonamide v reacting by heating in the presence of triphenylphosphine and diethylazodicarboxylate, obtain compound
i.
Formula i compound of the present invention has tyrosine kinase inhibitory activity, can be used for preparing tumor as effective ingredient
Medicine.The activity of formula i compound of the present invention is to be increased by vitro inhibition egfr and her2 kinases and suppression cell
Grow to test to verify.
The formula i compound of the present invention is effective in comparatively wide dosage range.The dosage for example taken daily about exists
In the range of 1mg-500mg/ people, it is divided into and being administered once or for several times.The actual dosage taking formula i compound can be by doctor's root
To determine according to relevant situation.
Specific embodiment
With reference to embodiment, the present invention is further illustrated.It should be noted that following embodiments are only for
Illustrate, and be not intended to limit the present invention.Those skilled in the art all should according to the various change that the teachings of the present invention is made
Within protection domain required by the application claim.
The synthesis of embodiment 1 compound i
The synthesis of step 1. compound iv-1
Compound ii (2.25g, 10mmol) is dissolved in the thf that 25ml is dried, and stirred under nitrogen atmosphere, with liquid nitrogen-ethanol
It is cooled to -78 DEG C, with the hexane solution (6.25ml) of the syringe slowly n-buli of Deca 1.6m, after completion of dropping, reaction
Mixture at such a temperature continue stir 1h, then again with syringe slowly Deca iii-1 (1.49g, 10mmol) be dissolved in 3ml do
The solution that dry thf makes.After completion of dropping, compound of reaction continues stirring 3 hours under being room temperature, and tlc display has been reacted
Become.Reactant mixture carefully pours in 200ml frozen water, and stirring, with 50ml × 3ch2cl2Extraction, merges extraction phase, uses saline
(100ml) wash, anhydrous sodium sulfate drying.Sucking filtration removes desiccant, and filtrate is evaporated on a rotary evaporator, obtains compound
Iv-1, white solid, esi-ms, m/z=340 ([m+h]+).
The synthesis of step 2. compound i
Diethylazodicarboxylate (dead, 1.74g, 10mmol) is dissolved in the thf that 20ml is dried, stirring, and ice-water bath is cold
But under, slowly Deca triphenylphosphine (2.62g, 10mmol) is dissolved in the solution that the dry thf of 5ml makes, and then adds compound
V (1.06g, 6mmol), mixture stirs 1 hour at such a temperature, adds compound iv-1 (2.03g, 6mmol).Reaction mixing
Thing reacts overnight at room temperature, then flows back 12 hours again.Tlc display reaction completes.Reactant mixture carefully pours into 200ml
In frozen water, stirring, with 50ml × 3ch2cl2Extraction, merges extraction phase, is washed with saline (100ml), anhydrous sodium sulfate drying.Take out
Filter desiccant, filtrate is evaporated on a rotary evaporator, obtain compound i, white solid, esi-ms, m/z=499 ([m+
h]+).
The synthesis of embodiment 2 compound r-1
The synthesis of step 1. compound iv-2
Compound ii (2.25g, 10mmol) is dissolved in the thf that 25ml is dried, and stirred under nitrogen atmosphere, with liquid nitrogen-ethanol
It is cooled to -78 DEG C, with the hexane solution (6.25ml) of the syringe slowly n-buli of Deca 1.6m, after completion of dropping, reaction
Mixture at such a temperature continue stir 1h, then again with syringe slowly Deca iii-2 (1.24g, 10mmol) be dissolved in 3ml do
The solution that dry thf makes.After completion of dropping, compound of reaction continues stirring 3 hours under being room temperature, and tlc display has been reacted
Become.Reactant mixture carefully pours in 200ml frozen water, and stirring, with 50ml × 3ch2cl2Extraction, merges extraction phase, uses saline
(100ml) wash, anhydrous sodium sulfate drying.Sucking filtration removes desiccant, and filtrate is evaporated on a rotary evaporator, obtains compound
Iv-2, white solid.Esi-ms, m/z=315 ([m+h]+).
The synthesis of step 2. compound r-1
Diethylazodicarboxylate (dead, 1.74g, 10mmol) is dissolved in the thf that 20ml is dried, stirring, and ice-water bath is cold
But under, slowly Deca triphenylphosphine (2.62g, 10mmol) is dissolved in the solution that the dry thf of 5ml makes, and then adds compound
V (1.06g, 6mmol), mixture stirs 1 hour at such a temperature, adds compound iv-2 (1.89g, 6mmol).Reaction mixing
Thing reacts overnight at room temperature, then flows back 12 hours again.Tlc display reaction completes.Reactant mixture carefully pours into 200ml
In frozen water, stirring, with 50ml × 3ch2cl2Extraction, merges extraction phase, is washed with saline (100ml), anhydrous sodium sulfate drying.Take out
Filter desiccant, filtrate is evaporated on a rotary evaporator, obtain compound r-1, white solid.Esi-ms, m/z=474 ([m
+h]+).
The suppression egfr and her2 analysis of embodiment 3 Compound ira vitro
Compound of the present invention can be measured using following experiment in vitro to erbb family tyrosine kinase (egfr
And her2) activity inhibition.
The vitro kinase assay htscan egfreceptor of cell signaling technology company
Kinase assay kit and htscan her2/erbb2kinaseassay kit detection.Operating procedure is with reference to test kit explanation
Book, the method detects that testing compound is made to the suppression of peptide substrate phosphorylation to egfr or her2 receptor tyrosine kinase in vitro
With.Incubate atp and peptide substrate and testing compound in kinase reaction buffer under room temperature, after incubation a period of time, add eventually
Stop liquid terminating reaction and transfer the sample in coated 96 orifice plates of Streptavidin, wash plate the anti-substrate phosphorus with hrp labelling
Phosphorylation level on acidifying antibody test peptide substrate, with tmb colour developing, 2m sulphuric acid stopped reaction.Detection 450nm absorbing wavelength,
Calculate ic50Value (nm).Result see table.
| Compound | egfr ic50(nm) | her2 ic50(nm) |
| Compound r-1 | 54 | 31 |
| Compound i | 7.6 | 7.9 |
The compound that can be seen that the present invention from upper table result has very strong inhibitory action to egfr and her2, permissible
As preparing anti-tumor drug.
The inhibitory action of embodiment 4 compound on intracellular propagation
Cell inhibitory effect test adopts human breast cancer cell bt474, SGC-7901 nci-n87, human lung carcinoma cell
Calu-3 and application on human skin cancerous cell a431, wherein bt474 high expression her2 receptor, n87 high expression egfr and her2 receptor.Containing
In dulbecco improvement eagle culture medium (dmem) of 10% hyclone, 2mm L-Glutamine and non essential amino acid, 37
DEG C, 5%co2Cultured cells in cell culture incubator, application trypsin/ethylenediaminetetraacetic acid (edta) is received from Tissue Culture Flask
Obtain cell.Cell adds 96 porocyte culture plates adherent overnight with 4000/ hole (0.1ml culture medium), adds 0.1ml test compounds
The diluent of thing, the ultimate density of dmso is 0.25%, by Tissue Culture Plate at 37 DEG C, 5% co2Under the conditions of incubate 72h.So
Examine under a microscope the change of cellular morphology afterwards, then every hole adds trichloroacetic acid (tca) the 50 μ l of 50% (mass/volume)
Fixing cell.Final concentration of the 10% of tca, places 1h in 4 DEG C of refrigerators after standing 5min, culture plate each hole deionized water is rushed
Wash 5 times, to remove tca, dry, air drying is to no wet mark.Every hole add 0.4% (mass/volume) srb 100 μ l, room temperature
Place 10min, rinsed 5 times with 1% acetic acid after discarding each in the hole liquid, air uses ph after being dried be 10.5,10mm tris (three
Hydroxymethyl aminomethane) 150 μ l extractions, the absorbing wavelength of detection 540nm.Result ic50Value (nm) see table.
As can be seen from the above table, the compound of the present invention has very high suppression to the tumor cell of the high expression of egfr and her2
System activity, can be used as preparing anti-tumor drug.
Claims (3)
1. formula i compound,
2. the method for formula i compound described in synthesis claim 1:
First with n-buli process, the aryl lithium intermediate obtaining and benzaldehyde iii react compound ii, obtain compound iv；Change
Compound iv and thiophene sulfonamide v reacting by heating in the presence of triphenylphosphine and diethylazodicarboxylate, obtain compound i.
3. purposes in terms of preparation treatment tumor disease medicine for the formula i compound described in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610659638.5A CN106336404A (en) | 2016-08-09 | 2016-08-09 | Benzoquinazolinetyrosine kinaseinhibitor containing fluorobenzene and thiophene-sulfonamide structure, and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610659638.5A CN106336404A (en) | 2016-08-09 | 2016-08-09 | Benzoquinazolinetyrosine kinaseinhibitor containing fluorobenzene and thiophene-sulfonamide structure, and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106336404A true CN106336404A (en) | 2017-01-18 |
Family
ID=57825234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610659638.5A Pending CN106336404A (en) | 2016-08-09 | 2016-08-09 | Benzoquinazolinetyrosine kinaseinhibitor containing fluorobenzene and thiophene-sulfonamide structure, and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106336404A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010015523A1 (en) * | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof |
| CN101648947A (en) * | 2002-03-30 | 2010-02-17 | 贝林格尔英格海姆法玛两合公司 | 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| CN101935316A (en) * | 2009-06-30 | 2011-01-05 | 江苏先声药物研究有限公司 | Quinazoline compound and application thereof |
-
2016
- 2016-08-09 CN CN201610659638.5A patent/CN106336404A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101648947A (en) * | 2002-03-30 | 2010-02-17 | 贝林格尔英格海姆法玛两合公司 | 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors |
| WO2010015523A1 (en) * | 2008-08-08 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy-substituted heterocyclics, medicines containing these compounds and method for the production thereof |
| CN101935316A (en) * | 2009-06-30 | 2011-01-05 | 江苏先声药物研究有限公司 | Quinazoline compound and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105001168A (en) | Tri-alkoxy-substituted benzo quinazoline type tyrosine kinase inhibitor and application thereof | |
| CN102838590B (en) | Amino quinazoline derivative and application thereof in preparation of antineoplastic drugs | |
| CN105017163A (en) | Bis(ethoxy) benzo quinazoline tyrosine kinase inhibitor as well as preparation method and application thereof | |
| JP2010518173A (en) | Salt form of 4-phenylaminoquinazoline derivative | |
| CN106336405A (en) | Benzoquinazolinetyrosine kinaseinhibitor containing thiophene-sulfonamide structure, and preparation method and application thereof | |
| CN106349230A (en) | Benzo-quinazoline tyrosine kinase inhibitor with nitrothiophene sulfamide structure and application | |
| CN106317040A (en) | Benzo quinazoline tyrosine kinase inhibitor containing thiophene-sulfonamide structure, preparation method and application | |
| CN106336404A (en) | Benzoquinazolinetyrosine kinaseinhibitor containing fluorobenzene and thiophene-sulfonamide structure, and application thereof | |
| CN106349231A (en) | Benzoquinazoline tyrosine kinase inhibitor containing halothiophene sulfonamide structure | |
| CN106432215A (en) | Benzo-quinazoline tyrosine kinase inhibitor containing thiophene sulfamide structure and application | |
| CN106317037A (en) | Ethoxy benzo quinazoline type tyrosine kinase inhibitor containing thiophenesulfonyl structure, preparation method and application | |
| CN106279135A (en) | A kind of Benzoquinazole class tyrosine kinase inhibitor of thiophenesulfonyl amine structure | |
| CN106317038A (en) | Thiophene-sulfamide structure containing benzoquinazoline tyrosine kinase inhibitor and application thereof | |
| CN106317039A (en) | Ethoxy benzo quinazoline type tyrosine kinase inhibitor containing thiophenesulfonyl structure, preparation method and application | |
| CN102216280B (en) | Bisarylurea derivatives and their use | |
| CN106699789A (en) | Benzoquinazoline tyrosine kinase inhibitor containing cyanoaryl boronic acid as well as preparation method and application | |
| CN106749368A (en) | The Benzoquinazole class tyrosine kinase inhibitor and purposes of a kind of amino-contained aryl boric acid | |
| CN106866715A (en) | Benzoquinazole class tyrosine kinase inhibitor containing aryl boric acid structure, Preparation method and use | |
| CN106831834A (en) | A kind of Benzoquinazole class tyrosine kinase inhibitor and purposes containing nitroaryl boric acid | |
| CN105085416A (en) | Nitro-substituted bisalcoxylbenzoquinazoline tyrosine kinase inhibitor and application | |
| CN106749370A (en) | Benzoquinazole class tyrosine kinase inhibitor and purposes of one class containing aryl boric acid structure | |
| CN106749367A (en) | The aryl boric acid Benzoquinazole class tyrosine kinase inhibitor of amino-contained phenyl, Preparation Method And The Use | |
| CN106831837A (en) | Aryl boric acid Benzoquinazole class tyrosine kinase inhibitor, Preparation Method And The Use of one class containing alkoxyphenyl radical | |
| CN106749371A (en) | The aryl boric acid Benzoquinazole class tyrosine kinase inhibitor and purposes of one class nitrile group-containing phenyl | |
| CN106831838A (en) | Aryl boric acid and Benzoquinazole class tyrosine kinase inhibitor containing alkoxy substitution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |